8-K: Exelixis Reports Q1 2026 Results, Announces New Stock Buyback

Exelixis announced strong first quarter 2026 financial results, driven by robust product revenues, and authorized an additional $750 million stock repurchase program.

Summary

• Exelixis reported first quarter 2026 total revenues of $610.8 million, an increase from $555.4 million in the prior year period.
• Net product revenues for the quarter reached $555.0 million, up from $513.3 million in Q1 2025, primarily due to increased sales volume.
• Collaboration revenues grew to $55.8 million from $42.2 million, driven by higher royalty revenues from Ipsen and milestone recognition.
• GAAP net income was $210.5 million, or $0.79 per diluted share, compared to $159.6 million, or $0.55 per diluted share, in Q1 2025.
• Non-GAAP net income was $232.8 million, or $0.87 per diluted share, an increase from $179.6 million, or $0.62 per diluted share, in Q1 2025.
• The company maintained its full-year 2026 financial guidance.
• Exelixis announced a new stock repurchase program of up to $750 million, authorized by the Board of Directors, to be completed by December 31, 2027.
• The New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer (CRC) was accepted by the FDA with a target action date of December 3, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with robust financial performance, significant pipeline advancements, and a commitment to shareholder returns through a new stock repurchase program.

Positives

• Total revenues increased by 10.0% year-over-year to $610.8 million.
• Net product revenues grew by 8.1% year-over-year to $555.0 million.
• Collaboration revenues increased by 32.4% year-over-year to $55.8 million.
• GAAP diluted EPS increased to $0.79 from $0.55, a 43.6% increase.
• Non-GAAP diluted EPS increased to $0.87 from $0.62, a 40.3% increase.
• The FDA accepted the NDA for zanzalintinib in metastatic CRC with a target action date of December 3, 2026.
• The company announced a new $750 million stock repurchase program, demonstrating confidence and commitment to shareholder returns.
• Full-year 2026 financial guidance was maintained.

Negatives

• Research and development expenses, while decreasing year-over-year, remain substantial at $199.9 million.
• Selling, general and administrative expenses increased slightly to $139.6 million from $137.2 million.

Risks

• The degree of market acceptance of CABOMETYX and other Exelixis products.
• Complexities and unpredictability of regulatory review and approval processes.
• Potential failure of cabozantinib, zanzalintinib, and other product candidates to demonstrate safety and/or efficacy in clinical testing.
• Dependence on relationships with collaboration partners, including their pursuit of regulatory approvals and adherence to agreements.
• Potential for competitors to obtain approval for generic versions of Exelixis marketed products.
• Uncertainties related to changing economic and business conditions, including trade policies and tariffs.

Future Outlook

Exelixis is maintaining its previously provided financial guidance for fiscal year 2026, with total revenues projected between $2.525 billion and $2.625 billion, and net product revenues between $2.325 billion and $2.425 billion. This guidance does not currently include any revenues from a potential U.S. regulatory approval and commercial launch of zanzalintinib for previously treated metastatic CRC. The company anticipates multiple milestones in 2026 for its zanzalintinib development program, including data readouts, enrollment advancements, and new trial initiations.

Management Comments

• "Exelixis made significant progress in the first quarter of 2026 as we remain focused on our goal of building next-generation oncology franchises."
• "Our first New Drug Application for zanzalintinib, for its initial potential indication in previously treated metastatic colorectal cancer, was accepted by U.S. regulatory authorities and is under active review, with a target action date of December 3, 2026."
• "As the cabozantinib franchise continues to grow and we execute across seven ongoing or soon-to-start pivotal studies for zanzalintinib, we remain committed to strengthening our leadership in GU and GI oncology to improve standards of care for patients and drive long-term value for our shareholders."
• "Our R&D organization is on track to deliver multiple milestones this year across our zanzalintinib pivotal development program."

Industry Context

StockSavvy.ai notes that Exelixis' strong Q1 2026 performance and continued investment in its pipeline, particularly with zanzalintinib, align with the broader industry trend of developing targeted therapies and combination treatments in oncology. The company's focus on building next-generation franchises and expanding its commercial reach reflects a strategic approach to sustained growth in a competitive landscape.

Comparison to Industry Standards

• Exelixis' Q1 2026 revenue growth of 10.0% outpaces the average revenue growth for many mid-cap biotechnology companies, which can fluctuate significantly based on pipeline progress and product launches.
• The company's GAAP diluted EPS of $0.79 and non-GAAP diluted EPS of $0.87 demonstrate strong profitability, comparing favorably to many peers in the oncology therapeutic area, where R&D investments are substantial.
• The FDA's acceptance of the zanzalintinib NDA with a standard review timeline is a positive indicator, reflecting the potential of the drug to meet regulatory standards, similar to other successful oncology drug approvals.
• The authorization of a new $750 million stock repurchase program signals financial strength and a commitment to shareholder value, a strategy employed by mature biopharmaceutical companies to return capital to investors.

Stakeholder Impact

• Shareholders: Benefit from strong financial results, increased EPS, and a new $750 million stock repurchase program, indicating potential for increased shareholder value.
• Patients: Potential future benefit from the advancement of zanzalintinib through regulatory review and clinical trials, aiming to improve standards of care in oncology.
• Employees: Continued focus on R&D and commercial expansion may lead to job growth and opportunities within the company.
• Collaboration Partners (e.g., Ipsen, Merck): Continued progress in clinical trials and regulatory submissions for partnered compounds like zanzalintinib benefits these relationships and potential future revenue streams.

Next Steps

• Complete the remainder of the October 2025 stock repurchase program in May 2026.
• Initiate the new $750 million stock repurchase program authorized in May 2026.
• Expect key data readouts from STELLAR-303 and STELLAR-304.
• Advance enrollment in STELLAR-311.
• Initiate STELLAR-316 in mid-2026.
• Initiate STELLAR-202 and the expansion cohort of STELLAR-002 in the second half of 2026.
• Present data on zanzalintinib and cabozantinib at ASCO 2026.

Key Dates

Recommendation

The company delivered strong Q1 2026 financial results with significant year-over-year growth in revenue and earnings per share. The FDA's acceptance of the zanzalintinib NDA and the authorization of a substantial new stock repurchase program further bolster confidence. Continued progress in the zanzalintinib pipeline and maintained full-year guidance suggest a positive trajectory, making it a strong buy for investors seeking growth in the oncology sector.

Keywords

Exelixis, 8-K, Financial Results, Q1 2026, Zanzalintinib, Cabozantinib, Stock Repurchase, Oncology